CL2025003919A1 - Proteínas de unión a receptor de linfotoxina beta agonistas. - Google Patents

Proteínas de unión a receptor de linfotoxina beta agonistas.

Info

Publication number
CL2025003919A1
CL2025003919A1 CL2025003919A CL2025003919A CL2025003919A1 CL 2025003919 A1 CL2025003919 A1 CL 2025003919A1 CL 2025003919 A CL2025003919 A CL 2025003919A CL 2025003919 A CL2025003919 A CL 2025003919A CL 2025003919 A1 CL2025003919 A1 CL 2025003919A1
Authority
CL
Chile
Prior art keywords
binding proteins
ltβr
beta agonists
lymphotoxin receptor
proteins beta
Prior art date
Application number
CL2025003919A
Other languages
English (en)
Spanish (es)
Inventor
Garces Fernando
Nevin Foltz Ian
Zhang Jun
Benjamin Case Ryan
NOUBADE Rajkumar
Yu WANG Hong
GONG Danyang
LAI Chin-Wen
Elaine Tinberg Christine
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2025003919A1 publication Critical patent/CL2025003919A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2025003919A 2023-06-12 2025-12-12 Proteínas de unión a receptor de linfotoxina beta agonistas. CL2025003919A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363472565P 2023-06-12 2023-06-12

Publications (1)

Publication Number Publication Date
CL2025003919A1 true CL2025003919A1 (es) 2026-01-23

Family

ID=91899198

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003919A CL2025003919A1 (es) 2023-06-12 2025-12-12 Proteínas de unión a receptor de linfotoxina beta agonistas.

Country Status (15)

Country Link
EP (1) EP4724490A2 (fr)
KR (1) KR20260025131A (fr)
CN (1) CN121399157A (fr)
AR (1) AR132931A1 (fr)
AU (1) AU2024305352A1 (fr)
CL (1) CL2025003919A1 (fr)
CO (1) CO2025018800A2 (fr)
CR (1) CR20260012A (fr)
IL (1) IL325097A (fr)
JO (1) JOP20250305A1 (fr)
MX (1) MX2025015224A (fr)
PE (1) PE20260306A1 (fr)
TW (1) TW202506733A (fr)
UY (1) UY40783A (fr)
WO (1) WO2024258870A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026122400A1 (fr) * 2024-12-03 2026-06-11 Amgen Inc. Protéines de liaison au récepteur b de lymphotoxine bispécifique

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR101115797B1 (ko) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
WO2007005612A2 (fr) 2005-07-01 2007-01-11 Medimmune, Inc. Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
WO2009077483A1 (fr) 2007-12-14 2009-06-25 Novo Nordisk A/S Anticorps humains anti-nkg2d et leurs utilisations
EA019595B1 (ru) 2007-04-17 2014-04-30 Имклоун Элэлси СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
AU2008275985B2 (en) 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
EP2236517A1 (fr) 2009-03-31 2010-10-06 Takara Bio, Inc. Anticorps monoclonal à fragment anti-fibronectine
CA2762720A1 (fr) 2009-05-21 2010-11-25 Tamarisk Technologies, L.L.C. Materiaux de construction a base d'alginate
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
CA2770174A1 (fr) 2009-08-31 2011-03-03 Roche Glycart Ag Anticorps monoclonaux anti-cea humanises obtenus par maturation d'affinite
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン１（ｍｕｃ１）タンパク質に対する抗体及びその用途
EP3904391B1 (fr) 2010-03-10 2024-07-10 Genmab A/S Anticorps monoclonaux contre c-met
KR20130108069A (ko) 2010-04-15 2013-10-02 알퍼 바이오테크, 엘엘씨 Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도
US8623369B2 (en) 2010-04-27 2014-01-07 National Research Council Of Canada Anti-ICAM-1 single domain antibody and uses thereof
WO2011139375A1 (fr) 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
JP2013534813A (ja) 2010-05-26 2013-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗ｃｄ１３３抗体一本鎖可変断片、及びこれらの使用
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
US8987423B2 (en) 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
KR20130048242A (ko) 2010-07-22 2013-05-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-종양 항원 항체 및 이용 방법
US20140093514A1 (en) 2011-06-03 2014-04-03 University Of Zurich Magea3 binding antibodies
CN107011439B (zh) 2011-07-15 2020-11-10 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用
EP2548891A1 (fr) 2011-07-18 2013-01-23 Universiteit Maastricht Anticorps monoclonal humain contre la subunité gamma du récepteur de l'acétylcholine pour une utilisation dans le traitement du rhabdomyosarcome
RU2015115956A (ru) 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
CN104884617B (zh) 2012-12-07 2019-02-19 协和发酵麒麟株式会社 抗folr1抗体
PT2953971T (pt) 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
CN105555804B (zh) 2013-08-07 2020-12-25 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
EP3143046B1 (fr) 2014-05-14 2020-06-17 F. Hoffmann-La Roche AG Protéines de liaison d'antigène her1 pour la liaison en épingle à cheveux bêta de her1
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3250611B1 (fr) 2015-01-26 2021-04-21 The University of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13r-alpha2 spécifique au cancer
US10711068B2 (en) 2015-03-26 2020-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD133 monoclonal antibodies and related compositions and methods
US10487153B2 (en) 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
RU2018102526A (ru) 2015-06-24 2019-07-25 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
CN109641954A (zh) 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
WO2018069871A2 (fr) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Protéines de liaison anti-kras
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
JP2020534370A (ja) 2017-09-21 2020-11-26 ユーエムセー ユトレヒト ホールディング ベイフェイＵＭＣ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 神経芽腫の治療のための抗ｇｄ２抗体
WO2019084553A1 (fr) 2017-10-27 2019-05-02 New York University Anticorps anti-galectine-9 et leurs utilisations
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
US11525010B2 (en) 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
BR112021002032A2 (pt) 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
AU2019359812A1 (en) 2018-10-15 2021-05-20 Board Of Regents, The University Of Texas System Monoclonal antibodies against human dickkopf3 and uses thereof
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途

Also Published As

Publication number Publication date
CR20260012A (es) 2026-03-09
PE20260306A1 (es) 2026-02-11
CO2025018800A2 (es) 2026-03-26
UY40783A (es) 2024-12-31
WO2024258870A8 (fr) 2025-12-11
WO2024258870A2 (fr) 2024-12-19
KR20260025131A (ko) 2026-02-23
AR132931A1 (es) 2025-08-13
TW202506733A (zh) 2025-02-16
CN121399157A (zh) 2026-01-23
EP4724490A2 (fr) 2026-04-15
MX2025015224A (es) 2026-02-03
IL325097A (en) 2026-02-01
JOP20250305A1 (ar) 2025-12-11
AU2024305352A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
CL2024002235A1 (es) Anticuerpo anti-cd73 humano; método de producción; composición farmacéutica; y su uso.
CL2024003715A1 (es) Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso.
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
MX2020008184A (es) Receptores de antigeno quimericos dirigidos a cd70.
MX2021001510A (es) Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
EA202091420A1 (ru) Радиоактивное мечение полипептидов
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CR20230302A (es) MÉTODO PARA TRATAR O MEJORAR TRASTORNOS METABÓLICOS MEDIANTE EL USO DE AGONISTAS DEL RECEPTOR Glp-1 CONJUGADOS CON ANTAGONISTAS DEL RECEPTOR DEL PÉPTIDO INHIBIDOR GÁSTRICO (GIPR) (Div. 2019-380)
MY199751A (en) Anti-igf-i receptor antibody
CL2021001790A1 (es) Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos
MX2017011534A (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
CL2021002294A1 (es) Compuestos, composiciones y métodos para el tratamiento de enfermedad
CO2025018800A2 (es) Proteínas de union a agonistas del receptor de linfoxina beta
PE20211708A1 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
UY39743A (es) Conjugados de anticuerpo anti-c-met y fármaco
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.